Day: September 18, 2020

Savosolar PlcCompany Announcement, Insider information    18 September 2020 at 2.15 p.m. (CEST)Savosolar statutory negotiations completed; temporary layoffs due to the corona situationThe statutory negotiations regarding Savosolar Plc’s corona position have been completed. The company has decided to lay off 21 people on a part-time or full-time basis for a maximum of 90 days over the next three months. The factory will continue its operations with a shortened working week according to the current plan until end of the year, as the company still has orders to fulfil. If the corona situation changes substantially during the three-month period, or if the company receives new orders during the lay-off period, the plan may be changed as necessary. The call back to work may take place with a three (3) days’ notice. The company has several projects...

Savosolar OyjYhtiötiedote, Sisäpiiritieto                            18.9.2020 klo 14.15 (CEST)Savosolarin yt-neuvottelut päätökseen; henkilöstöä lomautetaan koronatilanteen johdostaSavosolar Oyj:n koronatilanteesta johtuvat yt-neuvottelut on saatu päätökseen. Yhtiö on päättänyt lomauttaa 21 henkilöä osa- tai kokoaikaisesti, maksimissaan 90 päivän ajaksi seuraavan kolmen kuukauden aikana. Tehdas jatkaa toimintaansa lyhennetyllä työviikolla tämänhetkisen suunnitelman mukaan vuoden 2020 loppuun asti, koska yhtiöllä on edelleen tilauksia toteutettavana. Koronatilanteen muuttuessa kolmen kuukauden jaksolla olennaisesti tai mikäli yhtiö saa uusia tilauksia lomautusaikana, suunnitelmaa voidaan tarpeen mukaan muuttaa. Töihin takaisinkutsu voi tapahtua kolmen (3) päivän varoitusajalla.Yhtiöllä on useita projekteja aktiivisessa tarjous- ja toteutusvaiheessa,...

VANCOUVER, British Columbia, Sept. 18, 2020 (GLOBE NEWSWIRE) — Mission Ready Solutions Inc. (“Mission Ready” or the “Company”) (TSXV: MRS) is pleased to announce that, through its wholly-owned subsidiary, Unifire, Inc., the Company has been awarded a total of 7 government contracts – for personal protective equipment consisting of disposable level 2 and level 3 isolation gowns (the “Products”) – with an estimated value of $127,878,307 and a maximum value of $435,723,020 (the “C&T Contracts”) to be fulfilled over a 12-month period.As part of its COVID-19 pandemic response, the Contracts were awarded to the Company through the United States Defense Logistics Agency Troop Support Clothing & Textiles (“DLA C&T” or the “Contractor”) supply chain to facilitate the delivery of the Products to the United States Department...

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT AUTHORIZED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.TORONTO, Sept. 18, 2020 (GLOBE NEWSWIRE) — enCore Energy Corp. (TSXV:EU) (“enCore Energy Corp.” or the “Company”) announces that it has engaged Clarus Securities Inc. and PowerOne Capital Markets Limited (the “Agents”) to act as co-lead agents to raise up to $4,800,000 through a private placement offering of up to 12,000,000 units of the Company (the “Units”) at a price of $0.40 per Unit (the “Offering”). Each Unit is comprised of one common share in the capital of the Company (“Common Share”) and one half of one Common Share purchase warrant (each whole warrant a “Warrant”). Each Warrant shall entitle the holder to purchase one Common Share at an exercise...

SOUTH SAN FRANCISCO, Calif., Sept. 18, 2020 (GLOBE NEWSWIRE) — CytomX Therapeutics, Inc. (NASDAQ:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody® technology platform, today announced that on September 15, 2020, the Company granted nine new employees options to purchase a total of 211,000 shares of the Company’s common stock at an exercise price per share equal to $7.22, which was the closing trading price on September 15, 2020, the date of the grant. The stock options were granted pursuant to the Company’s 2019 Employment Inducement Incentive Plan, which was approved by the Company’s board of directors in August 2020 under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employees to enter into employment...

MALVERN, Pa., Sept. 18, 2020 (GLOBE NEWSWIRE) — Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced Gerri Henwood, the Company’s President and Chief Executive Officer, will present at the Oppenheimer Fall Healthcare Life Sciences & Medtech Summit on Tuesday, September 22, 2020 at 3:20 p.m. ET.A live webcast of the presentation will be available on the “Presentations” page within the Investors section of the Baudax Bio website at https://www.baudaxbio.com/news-and-investors. A replay will be available on the Baudax Bio website for a period of 30 days following the event.About Baudax BioBaudax Bio is a pharmaceutical company focused on therapeutics for acute care settings. The launch of the Company’s first commercial product, ANJESO®, began in June of 2020....

Series  RIKB 23 0515Settlement Date  09/23/2020Total Amount Allocated (MM)  7,500All Bids Awarded At (Price / Yield)  99.510 / 1.690Total Number of Bids Received  22Total Amount of All Bids Received (MM)  16,650Total Number of Successful Bids  13Number of Bids Allocated in Full  11Lowest Price / Highest Yield Allocated  99.510 / 1.690Highest Price / Lowest Yield Allocated  99.635 / 1.640Lowest Price / Highest Yield Allocated in Full  99.520 / 1.690Weighted Average of Successful Bids (Price/Yield)  99.575 / 1.660Best Bid (Price / Yield)  99.635 / 1.640Worst Bid (Price / Yield)  99.357 / 1.750Weighted Average of All Bids Received (Price / Yield)  99.524 / 1.680Percentage Partial Allocation (Approximate)  43.75 %Bid to Cover Ratio  2.22

Flokkur  RIKB 23 0515Greiðslu-og uppgjörsdagur  23.09.2020Samþykkt tilboð að nafnverði (m.kr.)  7.500Samþykkt (verð / ávöxtunarkrafa)  99,510 / 1,690Fjöldi innsendra tilboða  22Upphæð móttekinna tilboða að nafnverði (m.kr.)  16.650Fjöldi samþykktra tilboða  13Fjöldi samþykktra tilboða úthlutað að fullu  11Lægsta úthlutaða verð / Hæsta úthlutaða ávöxtunarkrafa  99,510 / 1,690Hæsta úthlutaða verð / Lægsta úthlutaða ávöxtunarkrafa  99,635 / 1,640Lægsta verð / Hæsta ávöxtunarkrafa úthlutað að fullu  99,520 / 1,690Vegið meðaltal samþykktra tilboða (verð / ávöxtunarkrafa)  99,575 / 1,660Besta tilboð (verð / ávöxtunarkrafa)  99,635 / 1,640Versta tilboð (verð / ávöxtunarkrafa)  99,357 / 1,750Vegið meðaltal innsendra tilboða (verð / ávöxtunarkrafa)  99,524 / 1,680Hlutfall samþykktra tilboða sem tekin...

GAINESVILLE, Ga., Sept. 18, 2020 (GLOBE NEWSWIRE) — Recro (Nasdaq:REPH), a leading contract development and manufacturing organization (CDMO), with integrated solutions for the development, formulation, regulatory support, manufacturing and packaging of oral solid dose drug products, today announced that Gerri Henwood, the Company’s President and Chief Executive Officer, will present at the Oppenheimer Fall Healthcare Life Sciences & Medtech Summit on Tuesday, September 22, 2020 at 4:10 p.m. ET.A live webcast of the presentation will be available on the “Presentations” page within the Investors section of the Recro website at https://ir.recropharma.com. A replay will be available on the Recro website for a period of 30 days following the event.About RecroRecro is a contract development and manufacturing, or CDMO, business,...

SAN DIEGO, Sept. 18, 2020 (GLOBE NEWSWIRE) — Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products, today announced that it will be added to the Russell 2000®  Index, effective when the U.S. market opens on Friday, September 18, 2020.The Russell 2000® Index measures the performance of the small-cap segment of the U.S. equity market. Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately $9 trillion in assets are benchmarked against Russell’s U.S. indexes. Russell indexes are part of FTSE Russell, a leading global index provider.About ProgenityProgenity, Inc. is a biotechnology company with an established track record...